InsidersTradesSigma
CUBE LABS SPA Stock: price and management transactions · Italy · Consob
Follow the CUBE LABS SPA stock price and the full insider trade history of the company, a publicly traded company based in Italy. Shares are quoted on IT IT, under the oversight of Consob. Operating in the Healthcare & Pharma sector, CUBE LABS SPA has recorded 8 public disclosures. Market capitalisation: €48.8m. The latest transaction was filed on 10 June 2026 (Purchase). Among the most active insiders: Keltinvest Srl. The full history is free.
8
Insider Decl.
0
Thresholds
€71,200
2 ops.
Buy Volume
€170,300
6 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate CUBE LABS SPA Strong Buy (bullish), based on 1 analysts. Average price target: €3.25.
36Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 18,957 of 25,973 companies
36.3
score / 100
Value24
Quality49
FCF yld-5.6%
Earn yld-1.5%
EV/EBITDA·
ROE·
Gross mgn84%
Net mgn-35%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 10 June 2026
Declarations8 total
10,000 shares@ €2.320.047% mcap32.6% of flowShareCONSOB:185656
Ideal exit: 2 Mar 2027 (T+270)
20,000 shares@ €2.400.12% mcap100.0% of flowShareCONSOB:183715
Ideal exit: 26 Dec 2026 (T+270)
2,500 shares@ €2.460.015% mcap100.0% of flowShareCONSOB:182436
●
PERSONA STRETTAMENTE ASSOCIATA A FILIPPO SURACE, PRESIDENTE DEL CONSIGLIO DIExecutives
2,500 shares@ €2.460.015% mcap3.7% of flowShareCONSOB:182429
●
PERSONA STRETTAMENTE ASSOCIATA A FILIPPO SURACE, PRESIDENTE DEL CONSIGLIO DIExecutives
20,000 shares@ €2.420.12% mcap29.5% of flowShareCONSOB:177252
●
PERSONA STRETTAMENTE ASSOCIATA A FILIPPO SURACE, PRESIDENTE DEL CONSIGLIO DIExecutives
10,000 shares@ €2.420.059% mcap14.7% of flowShareCONSOB:175856
●
PERSONA STRETTAMENTE ASSOCIATA A FILIPPO SURACE, PRESIDENTE DEL CONSIGLIO DIExecutives
17,500 shares@ €2.440.10% mcap26.0% of flowShareCONSOB:175852
●
PERSONA STRETTAMENTE ASSOCIATA A FILIPPO SURACE, PRESIDENTE DEL CONSIGLIO DIExecutives
17,500 shares@ €2.440.10% mcap26.0% of flowShareCONSOB:175007
8 of 8 declarations
About CUBE LABS SPA
Cube Labs S.p.A. is an Italian healthcare technology venture builder listed on Borsa Italiana (FTSE MIB) through the Euronext Growth Milan Professional segment. Founded in 2013, the company was built around a focused investment and incubation thesis: turning high-quality academic research into commercially viable companies and products in the life sciences sector. Its registered office is in Rome, with secondary offices in Maglie and Milan, underscoring a primarily Italian operating base while retaining an outward-looking, international ambition. Cube Labs’ business model combines spin-off creation, equity participation, operational support and R&D project development. In practice, the company acts as a bridge between universities, research institutes, clinicians and the market, contributing capital, governance, development expertise and access to industrial partners. Its core exposure is concentrated in medtech, biotech, pharma and broader healthcare technologies. The most visible portfolio and project names include Adamas Biotech, DTech, Biodiapers, Cartilago, Lipovexa and FluoDetect, alongside initiatives connected to digital platforms, medical devices, therapeutic applications and nutraceutical solutions. From a competitive standpoint, Cube Labs differentiates itself from a conventional financial investor by using a highly hands-on venture-building approach. This niche positioning allows it to source intellectual property originating in academia and structure it into dedicated vehicles with medium-term value-creation potential. The strategy is attractive in a European context where academic-to-commercial translation is still fragmented and under-monetised. For investors, that creates an interesting growth optionality profile, but also a higher risk level than a mature industrial company, given the dependence on project execution, regulatory pathways and financing rounds. Recent highlights include continued capital increases, the creation of new spin-offs in 2024, public and scientific support for certain portfolio companies, and new R&D partnerships in Italy and abroad. Cube Labs has also announced progress on patent protection, industrial collaboration and commercial development, notably in digital health and regenerative technologies. Overall, the stock remains a thematic small-cap growth story, driven by its pipeline, its ability to convert scientific IP into enterprise value, and its capital allocation discipline. The company’s market listing on Borsa Italiana (FTSE MIB) in Italy gives it visibility, but the investment case remains anchored in long-duration venture-building economics rather than short-term earnings power.
